OVERVIEW
This case-based interactive symposium will start by providing an introduction on the clinical implications of the new risk assessment strategies, followed by a clinical case discussion to provide guidance on the management of patients with high-risk non-muscle invasive bladder cancer (NMIBC). We continue the program with an update on emerging neoadjuvant intravesical therapies and treatment options for bacillus Calmette-Guérin (BCG)-unresponsive disease. Finally, a clinical case of a patient with very high-risk NMBIC will be presented and the experts will discuss the available therapeutic treatment strategies. Attendees will have the opportunity to submit questions to be addressed throughout the program. [bold]To participate in this in-person event (Amsterdam) you must be registered for EAU22, Amsterdam.[/bold]
GOAL STATEMENT
The goal of this activity is to educate physicians on best practices for risk stratification of non-muscle invasive bladder cancer (NMIBC), and how to optimally manage patients with high risk and very high risk NMIBC.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST][ITEM]Latest guideline recommendations for risk stratification of NMIBC [/LIST]Have greater competence related to [LIST] [ITEM]Applying the latest recommendations for the management of patients with high-risk NMIBC [/LIST]Demonstrate greater confidence in their ability to [LIST] [ITEM]Understand the clinical implications of the latest data investigating novel treatment approaches in NMIBC [/LIST]
ACCREDITATION STATEMENT
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.5 continuing professional development credits (CPD). [WEBMDGLOBAL]
RAI Amsterdam
Europaplein 24, Room: 3
Amsterdam, , 1078 GZ
The Netherlands
Supported by an independent educational grant from [bold]Medac[/bold].